Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A NEW MOUSE MODEL OF EXPERIMENTAL MELANOMA FOR VACCINE AND LYMPHOKINETHERAPY
Autore:
SHRAYER DP; BOGAARS H; HEARING VJ; WOLF SF; WANEBO HJ;
Indirizzi:
BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT SURG,SURG ONCOL RES LAB,825 CHALKSTONE AVE PROVIDENCE RI 02908 GENET INST INC CAMBRIDGE MA 02140 NCI,CELL BIOL LAB,NIH BETHESDA MD 20892
Titolo Testata:
International journal of oncology
fascicolo: 2, volume: 13, anno: 1998,
pagine: 361 - 374
SICI:
1019-6439(1998)13:2<361:ANMMOE>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
FORMALINIZED EXTRACELLULAR ANTIGENS; PURIFIED GM2 GANGLIOSIDE; AUTOREACTIVE T-CELLS; MURINE MELANOMA; TUMOR REJECTION; ADJUVANT IMMUNOTHERAPY; MONOCLONAL-ANTIBODIES; PROTEOGLYCAN ANTIGEN; PULMONARY METASTASIS; PLATELET-AGGREGATION;
Keywords:
MELANOMA; POLYVALENT ANTIGEN; MONOVALENT ANTIGEN; IMMUNIZATION; POLYCLONAL ANTIBODY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
96
Recensione:
Indirizzi per estratti:
Citazione:
D.P. Shrayer et al., "A NEW MOUSE MODEL OF EXPERIMENTAL MELANOMA FOR VACCINE AND LYMPHOKINETHERAPY", International journal of oncology, 13(2), 1998, pp. 361-374

Abstract

The annual incidence of malignant melanoma is estimated at 10-12 per 100,000 inhabitants in countries of central Europe and the United States, and alarmingly there has been a dramatic upward trend in that estimate. The B16 murine melanoma in a rapidly growing metastatic tumor ofspontaneous origin, as are human malignant melanomas. Melanoma cells produce specific antigens which are uniquely different from normal cellular antigens, and the expression of such antigens is the cornerstonefor preparation of anti-melanoma vaccines. One major problem in evaluating the effectiveness of vaccination and other biologic therapies isthe variability of experimental tumor models. A new metastatic model of experimental melanoma which was developed in our laboratory imitates the major clinical stages of malignant metastatic melanoma: stage I,primary (local) tumor growth and bone marrow invasion; stage II, regional lymph node involvement; and stage III, metastasis to distant organs, such as the lungs. This model has been used successfully for screening vaccines constructed in our laboratory. Immunization with formalinized vaccines (of extracellular antigens, intact melanoma cells, or B700 antigen) or irradiated vaccines (of intact melanoma cells) partially inhibit primary melanoma tumor growth, reduce metastasis to regional lymph nodes and lungs, and significantly increase mean survival time. These anti-tumor effects were improved when polyvalent and monovalent vaccines were combined with IL-2 therapy. We also compared the immunogenic activity of vaccines made from B16 melanoma cells transfected with genes encoding murine IL-2 or GM-CSF, and effects on tumor bearingmice were compared with or without therapy using the corresponding lymphokines. In sum, comparison of antibody production, growth of primary melanoma tumors, number of surviving mice, mean survival time, and percent of mice with lung metastases, showed that the best course of immunotherapy involves vaccination of mice with irradiated B16 melanoma cells transfected to secrete GM-CSF, coupled with GM-CSF therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 20:56:00